Hologic, Inc. (NASDAQ:HOLX) Receives Average Rating of “Hold” from Brokerages

Shares of Hologic, Inc. (NASDAQ:HOLX) have been assigned a consensus recommendation of “Hold” from the twenty analysts that are presently covering the stock, MarketBeat.com reports. Fifteen investment analysts have rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $79.6667.

A number of research firms have commented on HOLX. Leerink Partners raised their price target on Hologic from $70.00 to $78.00 and gave the company a “market perform” rating in a report on Tuesday, October 21st. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $78.00 target price on shares of Hologic in a research report on Wednesday, October 22nd. Needham & Company LLC reissued a “hold” rating on shares of Hologic in a research note on Tuesday, November 4th. BNP Paribas cut Hologic from a “strong-buy” rating to a “hold” rating and set a $79.00 price target on the stock. in a report on Friday, November 21st. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of Hologic in a report on Friday, October 31st.

Insiders Place Their Bets

In other Hologic news, CEO Stephen P. Macmillan sold 138,358 shares of the business’s stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. The trade was a 10.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christiana Stamoulis sold 7,402 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $73.07, for a total value of $540,864.14. Following the transaction, the director owned 47,336 shares of the company’s stock, valued at approximately $3,458,841.52. The trade was a 13.52% decrease in their position. The disclosure for this sale is available in the SEC filing. 1.88% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hologic

Hedge funds have recently made changes to their positions in the company. Chung Wu Investment Group LLC purchased a new position in Hologic during the 2nd quarter valued at approximately $26,000. Winnow Wealth LLC bought a new stake in Hologic in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd raised its holdings in shares of Hologic by 193.6% during the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 414 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 273 shares in the last quarter. Root Financial Partners LLC bought a new position in shares of Hologic during the 3rd quarter valued at approximately $27,000. Finally, SJS Investment Consulting Inc. grew its holdings in shares of Hologic by 341.5% in the third quarter. SJS Investment Consulting Inc. now owns 468 shares of the medical equipment provider’s stock valued at $32,000 after purchasing an additional 362 shares in the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Up 0.1%

NASDAQ:HOLX opened at $74.97 on Friday. Hologic has a one year low of $51.90 and a one year high of $80.31. The business has a fifty day moving average price of $72.28 and a 200-day moving average price of $67.68. The firm has a market capitalization of $16.71 billion, a price-to-earnings ratio of 30.23, a price-to-earnings-growth ratio of 2.14 and a beta of 0.70. The company has a debt-to-equity ratio of 0.50, a current ratio of 3.75 and a quick ratio of 3.06.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings data on Monday, November 3rd. The medical equipment provider reported $1.13 EPS for the quarter, beating the consensus estimate of $1.10 by $0.03. Hologic had a net margin of 13.80% and a return on equity of 20.13%. The firm had revenue of $1.05 billion for the quarter, compared to the consensus estimate of $1.03 billion. During the same period last year, the firm earned $1.01 EPS. The company’s revenue was up 6.2% on a year-over-year basis. Sell-side analysts forecast that Hologic will post 4.28 EPS for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.